Europe-Africa Research Network for Evaluation of Second-line Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1277 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good clinical outcome following WHO-defined failure on a first-line nucleoside reverse transcriptase inhibitor (NRTI) and NNRTI-containing regimen with probable extensive NRTI and NNRTI resistance mutations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

NCT00928187

HIV HIV Infections

COMPLETED PHASE3

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

NCT01605890

HIV-2 Infection

COMPLETED PHASE2

Nucleosides And Darunavir/Dolutegravir In Africa

NCT03988452

Human Immunodeficiency Virus

UNKNOWN PHASE3

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS

NCT02155101

HIV/AIDS

COMPLETED PHASE3

Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens

NCT02689895

HIV

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The standard of care for second-line HIV therapy in patients who have failed a first-line NNRTI-based regimen is to combine a boosted protease inhibitor (bPI) with two (new) NRTIs. However, patients failing first-line therapy in roll-out programmes often have extensive NRTI resistance mutations that may compromise the efficacy of the NRTI drugs used in second-line therapy and it is likely that the virological potency of the second-line regimen is mostly due to the bPI. It is possible that the contribution of the NRTI drugs to efficacy may be outweighed by additional toxicity and cost. It is also possible that replacing the NRTI drugs with a new class of drug (integrase inhibitors) will improve outcome from second-line therapy, although if the boosted protease inhibitor alone is providing close to optimal response, incremental gains from adding a new class may be small.

The principal aims are to determine whether, in patients failing a first-line NRTI and NNRTI-containing regimen:

* The use of bPI plus raltegravir (an integrase inhibitor) is superior to standard of care (bPI plus 2 new NRTIs) in achieving good HIV disease control at 96 weeks after randomisation
* The use of bPI monotherapy, preceded by a 12-week induction period in combination with raltegravir, is non-inferior to standard of care in achieving good HIV disease control at 96 weeks after randomisation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bPI + 2NRTIs

Group Type ACTIVE_COMPARATOR

Aluvia + 2NRTIs

Intervention Type DRUG

Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily

The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.

bPI + raltegravir

Group Type EXPERIMENTAL

Aluvia + raltegravir

Intervention Type DRUG

Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily

raltegravir (400mg) twice daily

bPI monotherapy

Group Type EXPERIMENTAL

Aluvia monotherapy

Intervention Type DRUG

Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily

raltegravir (400mg) twice daily for the first 12 weeks only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aluvia + 2NRTIs

Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily

The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.

Intervention Type DRUG

Aluvia + raltegravir

Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily

raltegravir (400mg) twice daily

Intervention Type DRUG

Aluvia monotherapy

Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily

raltegravir (400mg) twice daily for the first 12 weeks only

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previously documented HIV infection on at least one standard antibody-based test
* Age 12 years and above
* Taking 2NRTI + NNRTI-based regimen continuously for at least 12 months
* Naive to protease inhibitor therapy
* Good adherence to ART in the 12 weeks prior to screening defined as missing medication on no more than 3 days in the prior month
* Clinically stable and receiving treatment for any known opportunistic infections
* HIV treatment failure defined by one or more of clinical, immunological or virological criteria defined in the protocol, including VL and CD4 at screening visit
* Willing and able to give informed consent
* Able to attend for regular study follow up visits

Exclusion Criteria

* Any major clinical contra-indications to the use of bPI, the NRTIs that are available to be selected for a second-line regimen or raltegravir
* Known Hepatitis B carrier (Hepatitis B surface antigen positive if tested)
* Requires concomitant medication with known major interactions with study drugs for which drug substitutions or dose alterations are not available or acceptable
* Women who are currently pregnant or breastfeeding
* Current participation in another clinical trial involving a treatment intervention (may be permitted in some circumstances, but must be discussed with MRC CTU)
* Life expectancy of less than one month in the opinion of the treating physician

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No